Amneal Pharmaceuticals (AMRX) Bets Big On Biosimilars While Wall Street Retreats
At a glance
- $AMRX today−0.52%last $21.12
- Vs industry peers+0.69 pts6-peer median −1.20% · ahead
- Since Sep 4+23.9%from the first trade after the story
- 52-week range4.3% below high$11.39 – $22.07
- Last reported loss$21.7Mquarter to Sep 30, 2026 · 10-Q
- Coverage1 this week1 in 30 days · too few stories to call a pace
Nothing reported about amneal across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: In healthcare, the calendar is the catalyst: trial readouts, FDA dates and pricing rules drive most of the moves.
- How the stock is trading: $AMRX -0.52% in the latest session.
- Timing: It was published while New York was trading, so the day's move may already include the first reaction.
Where the stock stands
Amneal Pharmaceuticals ($AMRX) slipped 0.52% to $21.12 in the latest session. Over the past month it is up 9.1%. That leaves it 4.3% below its 52-week high of $22.07 and 85% above its low of $11.39, close to the top of its range. The high sits 94% above the low, a wide range for one year.
What the filings say
In its latest report (10-Q, filed Nov 9, 2026), $AMRX lost $21.7M over the quarter to Sep 30, 2026 on revenue of $862.7M (+8.4% QoQ). Operations brought in $50.3M of cash over the nine months to Sep 30, 2026; after capital spending, free cash flow was negative at $20.3M. It carried $2.94B of debt against $157.4M of cash on Sep 30, 2026 — net debt of $2.78B. Its most recent filings before this story: 8-K on Aug 10, 2026, 10-Q on Aug 6, 2026, 8-K on Aug 3, 2026. Figures are as filed with the SEC; the $AMRX page has the full statements.
How much coverage it is getting
This story is more than a month old. Since then Wook has filed one newer story on Amneal Pharmaceuticals, published this week. It reads bullish.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Wook's supply-chain scanner shows no unusual stress in Health Care today.
Coming up
Monthly options expiration in 3 days and FOMC decision in 22 days. These dates were set well before this story broke. The first lands 3 days away, when hard numbers start to replace the headlines.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $AMRX page, and they say what management has disclosed without a reporter in between. Where several outlets agree is usually the news; where they differ is the angle. To run the numbers yourself, ask Wook AI above about $AMRX: its distance from the high, its last report, or how coverage has changed.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Yahoo Finance published this on September 4, 2026. $AMRX has moved +23.87% ($17.05 to $21.12). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
